分子标志物肺-molGPA在非小细胞肺癌脑转移中的验证
本研究在269例德国和挪威非小细胞肺癌脑转移患者中验证Lung-molGPA预后模型,所有患者均接受脑放疗。中位生存期5.4个月,评分可预测腺癌及其他类型患者的生存,但7个预后分层中有6层中位生存期短于原始模型。
要点
- Lung-molGPA在独立欧洲数据集中验证有效,可预测非小细胞肺癌脑转移患者生存。
- 腺癌患者4个预后分层中位生存期分别为3.0、6.2、14.7和25.0个月。
- 非腺癌患者3个预后分层中位生存期分别为2.4、5.5和12.5个月。
核心结论
- Lung-molGPA在来自不同地理区域的独立数据集中得到验证,但7个预后分层中有6个中位生存期短于原始模型。
研究设计与样本
- 回顾性研究纳入269例德国和挪威非小细胞肺癌脑转移患者,均接受个体化治疗且始终包含脑放疗。
- 收集年龄、颅外转移、脑转移数目、体能状态、组织学类型、EGFR和ALK改变信息,按Sperduto等所述计算Lung-molGPA评分。
主要发现
- 全组中位生存期为5.4个月。
- 腺癌患者4个预后分层中位生存期分别为3.0、6.2、14.7和25.0个月。
- 非腺癌患者3个预后分层中位生存期分别为2.4、5.5和12.5个月。
- 评分可预测腺癌组织学及其他类型患者的生存。
关键数值与推荐
- 腺癌4个预后分层中位生存期分别为3.0、6.2、14.7和25.0个月。
- 非腺癌3个预后分层中位生存期分别为2.4、5.5和12.5个月。
临床怎么用
- Lung-molGPA可用于非小细胞肺癌脑转移患者的预后分层,辅助个体化治疗决策。
局限性
- 回顾性研究设计。
- 6/7预后分层中位生存期短于原始模型,可能解释包括领先时间偏倚及脑转移定向和全身治疗选择差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Many patients with brain metastases from non-small cell lung cancer have limited survival, while others survive for several years, depending on patterns of spread, EGFR and ALK alterations, among others. The purpose of this study was to validate a new prognostic model (Lung-molGPA) originally derived from a North American database. PATIENTS AND METHODS: This retrospective study included 269 German and Norwegian patients treated with individualized approaches, always including brain radiotherapy. Information about age, extracranial spread, number of brain metastases, performance status, histology, EGFR and ALK alterations was collected. The Lung-molGPA score was calculated as described by Sperduto et al. RESULTS: Median survival was 5.4 months. The score predicted survival in patients with adenocarcinoma histology and those with other types. For example, median survival was 3.0, 6.2, 14.7 and 25.0 months in the 4 different prognostic strata for adenocarcinoma. The corresponding figures were 2.4, 5.5 and 12.5 months in the 3 different prognostic strata for non-adenocarcinoma. CONCLUSIONS: These results confirm the validity of the Lung-molGPA in an independent dataset from a different geographical region. However, median survival was shorter in 6 of 7 prognostic strata. Potential explanations include lead time bias and differences in treatment selection, both brain metastases-directed and systemically.
引用
- Nieder C, Hintz M, Oehlke O, et al. Validation of the graded prognostic assessment for lung cancer with brain metastases using molecular markers (lung-molGPA). Radiat Oncol. 2017. PMID: 28651600. doi:10.1186/s13014-017-0844-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。